Benefits of Fish Oil

Evidence-Based Benefits

• Cardiovascular event reduction — The REDUCE-IT trial (Bhatt et al., 2019) randomized 8,179 statin-treated patients with elevated triglycerides to 4g icosapent ethyl (high-purity EPA) or placebo; EPA reduced major adverse cardiovascular events by 25%, ischemic events by 26%, and cardiovascular death by 20%, establishing high-dose EPA as a prescription-grade cardiovascular intervention
• Triglyceride reduction — A Cochrane meta-analysis by Abdelhamid et al. (2020) confirmed that omega-3 supplementation reliably reduces triglycerides by 15-30% at standard doses (2-4g EPA+DHA), with effects dose-dependent and most pronounced in hypertriglyceridemic patients; this is the most robust and reproducible effect of fish oil supplementation
• Depression and mood improvement — Liao et al. (2019) published a meta-analysis of 26 RCTs showing omega-3 supplementation significantly improved depressive symptoms compared to placebo, with EPA-predominant formulations (≥60% EPA) showing the largest effect sizes; DHA-predominant formulations were less effective for depression specifically
• Anti-inflammatory effects — Calder (2017) reviewed the mechanisms by which EPA and DHA reduce inflammation: they compete with arachidonic acid for COX-2 and LOX enzymes, reduce pro-inflammatory prostaglandins and leukotrienes, and generate specialized pro-resolving mediators (resolvins and protectins) that actively resolve inflammation rather than merely suppressing it
• Joint pain and arthritis relief — Goldberg & Katz (2007) meta-analyzed 17 RCTs and found that omega-3 supplementation significantly reduced joint pain intensity and morning stiffness in patients with rheumatoid arthritis and inflammatory joint disease, with some patients able to reduce NSAID use

What the Research Says

Fish oil has the deepest evidence base of any nutritional supplement. The REDUCE-IT trial (Bhatt et al., 2019, NEJM) is the landmark study: 8,179 statin-treated patients with elevated triglycerides randomized to 4g icosapent ethyl (purified EPA) or placebo showed a 25% reduction in major adverse cardiovascular events — the first supplement trial to demonstrate hard cardiovascular endpoint reduction at this magnitude. A 2020 Cochrane review by Abdelhamid et al. analyzed 86 RCTs and confirmed omega-3s reliably reduce triglycerides and may slightly reduce coronary heart disease events and mortality, though effects on total mortality were less clear. For depression, Liao et al. (2019) meta-analyzed 26 RCTs and found significant benefit, particularly with EPA-dominant formulations at doses above 1g/day. Calder (2017) elucidated the anti-inflammatory mechanisms: EPA and DHA compete with arachidonic acid for COX-2/LOX enzymes and generate specialized pro-resolving mediators (resolvins, protectins, maresins) that actively resolve — rather than merely suppress — inflammation. Goldberg & Katz (2007) meta-analyzed 17 RCTs showing significant joint pain reduction in inflammatory arthritis. The evidence for cognitive decline prevention in healthy adults is weaker, though DHA is a structural component of brain cell membranes. Bioavailability research shows re-esterified triglyceride (rTG) form is 70% better absorbed than ethyl esters.

Related Conditions